Clinical Invest Jnl

Clinical Investigation Journal | Expert analysis of ongoing Phase I–IV trials and perspectives on how to run future trials | Published by Future Science Group

[Clinical Invest Jnl @fsgcli]

#SciArt: Confocal micrograph of Bacillus subtilis from @wellcomeimages. http://t.co/bk3vzPRwDU @BioanalysisZone

[Clinical Invest Jnl @fsgcli]

Clinical Investigation Reviews Approaches and Outcomes of HIV Trials in Africa - http://t.co/e2hrjCZjS6

[Clinical Invest Jnl @fsgcli]

Monitoring clinical trials in a developing nation is a great learning opp! Read more in Clinical Investigation - http://t.co/nHay1J9Cw0

[Clinical Invest Jnl @fsgcli]

Webinar registration open: Gene-modified MSCs as a potential treatment for #Huntington's disease http://t.co/Ih3DfBVxmb @RegMedNet @ucdavis

[Clinical Invest Jnl @fsgcli]

Merck & Co. says #diabetes drug Januvia meets main goal of cardiovascular outcomes study http://t.co/lvVzpZdpv8 #clinicaltrials @fsgdmt

[Clinical Invest Jnl @fsgcli]

Investigational #shingles #vaccine maintains efficacy across age groups: study http://t.co/G8dt8mROZ8 @fsgfmb

[Clinical Invest Jnl @fsgcli]

#openaccess article: Multi-arm #clinicaltrials with treatment selection http://t.co/dOn5da6zHj By Dr Jaki @LancasterUni. @fsgfso

[Clinical Invest Jnl @fsgcli]

#openaccess editorial: The #adaptive #clinicaltrials opportunity for #biotech and smaller #pharmaceutical companies http://t.co/zTwpp9TB9t

[Clinical Invest Jnl @fsgcli]

FDA approves first generic versions of Otsuka's #Abilify http://t.co/lCbeDVZSpI @fsgneurology #bipolardisorder #Schizophrenia

[Clinical Invest Jnl @fsgcli]

#openaccess Check out the foreword to our special focus issue on #adaptive #clinicaltrials http://t.co/AJwK16Ipjq by Dr Antonijevic @cytel

[Clinical Invest Jnl @fsgcli]

Our #adaptive #clinicaltrials special-focus issue is online! I'll be tweeting amazing #openaccess content today http://t.co/sCHIYvw60C

[Clinical Invest Jnl @fsgcli]

Thanks @fsgfso - there's some great #openaccess content available! https://t.co/if2LoXVyVP

[Clinical Invest Jnl @fsgcli]

Europe OKs First Programmed Death Inhibitor, #Nivolumab http://t.co/JKdfeXbz9u @fsgimt @fsgfon #Melanoma

[Clinical Invest Jnl @fsgcli]

.@ucdavis researchers to present #webinar on genetically engineered #MSCs for #Huntingtons http://t.co/0P9hEFTI8V

[Clinical Invest Jnl @fsgcli]

Experimental drug safe, effective in #Schizophrenia http://t.co/u9PYKrAeiS @fsgneurology #mentalhealth

[Clinical Invest Jnl @fsgcli]

CHMP issues positive opinion for Bristol-Myers Squibb's #Opdivo in advanced #melanoma http://t.co/jve13OAwgw @fsgijh

[Clinical Invest Jnl @fsgcli]

Inaccurate reporting jeopardising #clinicaltrials http://t.co/DDPTRheFDp research via @OfficialUoM

[Clinical Invest Jnl @fsgcli]

@BergHealth we're annoyed we missed Dr Narain's talk in Boston, sounds like it would make a great editorial though!

[Clinical Invest Jnl @fsgcli]

Actavis announces phase3 #clinicaltrial results for Dalbavancin #MRSA http://t.co/y9rBDct2js @fsgfmb

[Clinical Invest Jnl @fsgcli]

FDA: orphan drug designation for DCR-PH1, investigational therapy for the treatment of PH1 http://t.co/1s7UBembKy

[Clinical Invest Jnl @fsgcli]

FDA weighs tighter regulation of #homeopathic medicines http://t.co/RNUfkgEps5